We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · July 26, 2020

US Stock Market Response to FDA Approval of New Dermatologic Drugs

Journal of Drugs in Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Drugs in Dermatology
United States Stock Market Response to FDA Approval of New Dermatologic Drugs
J Drugs Dermatol 2020 Jun 01;19(6)639-645, RS Mazmudar, R Tripathi, HH Ezaldein, JF Scott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading